ClinicalTrialsFinder

IDH-mutant Grade 2 or 3 Astrocytoma Clinical Trials in Birmingham

1 recruitingBirmingham, United Kingdom

Showing 1–1 of 1 trials

Recruiting
Phase 3

Vorasidenib Maintenance for IDH Mutant Astrocytoma

IDH-mutant Grade 2 or 3 Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC468 enrolled33 locationsNCT06809322